Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Grace Therapeutics, Inc GRCE

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.


NDAQ:GRCE - Post by User

Post by EternalPonzion Sep 01, 2020 4:10am
348 Views
Post# 31484925

Are you primarily what you eat and do?

Are you primarily what you eat and do?
Although I am unsurprised by the T2 outcome, I'm left to wonder what the results would have been if participants were not on any type of diet or exercise program. Eat what and when you want, do what you want but have participants keep a diary of their daily diet and activity level. Granted, the primary endpoint analysis of such a sample group, of sufficient size to ensure statistical significance, would be problematic as there would be many variables in play. Are secondary endpoints affected whether diet/exercise in play? Which leads me to this question; Does taking vitamin supplements, or just one daily multivitamin, actually provide any benefit to someone with a decent diet or is a vast majority of the supplement market a scam. If not a scam, can CaPre be marketed as a unique best in category supplement (would advise against calling it another Omega 3 type as that category is far too crowded), albeit a relatively expensive one given the process by which CaPre is manufactured. Would people be willing to take one massive pill or even be bothered to take 2 or 3 smaller pills each day and pay the price given the economic climate we find ourselves in for the foreseeable future? I'm thinking not, unless people truly can be made to believe it is necessary and/or of benefit to one's health - quite the problem for marketers/advertisers to tackle depending on what the regulatory environment allows. Thousands religiously take the aforementioned multivitamin daily because they believe it is of benefit - which may or may not be the case depending on lifestyle. Even though CaPre did not reach SS in T2 it is hard to argue that this product has absolutely no measurable benefit. Can they monetize this benefit is the question?
<< Previous
Bullboard Posts
Next >>